FibroBiologics Secures European Patent for Sox9-Based Cartilage Regeneration Gene Therapy

A European patent grant covering fibroblast-to-chondrocyte conversion puts FibroBiologics in a stronger IP position across major EPC-designated markets, with direct implications for how the company's orthopedics and degenerative disc programs advance toward clinical and eventual commercial manufacturing.

The European Patent Office has granted EP 3043825 B1, titled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells." The patent's 12 claims cover compositions comprising one or more expression vectors encoding therapeutic polynucleotides, including Sox9, for use in cartilage repair. Granted claims extend to delivery of those vectors to fibroblast cells that then differentiate into chondrocytes or cartilage-type cells, use of both viral and non-viral vectors, and combinations of Sox9 with additional therapeutic genes on single or multiple vectors.

The biological rationale is grounded in cartilage's structural limitations. Cartilage is avascular, aneural, and hypoxic, properties that have historically made it resistant to regenerative intervention and confined clinical options to tissue grafting or joint replacement. The granted claims address delivery in that low-oxygen environment by instructing resident fibroblasts to adopt a chondrocyte phenotype and produce cartilage matrix components in situ, rather than introducing exogenous tissue or hardware.

For development and manufacturing teams beginning to model process requirements, the claim scope carries practical weight. Coverage of both viral and non-viral vector modalities, alongside multi-gene construct configurations, signals that FibroBiologics retains flexibility in vector platform selection. That flexibility will bear on upstream process development decisions, including vector production scale, fill-finish requirements, and the sterility assurance considerations that accompany advanced therapy medicinal product manufacturing under applicable GMP frameworks.

FibroBiologics currently holds more than 270 issued and pending patents across pathways that include wound healing, multiple sclerosis, disc degeneration, psoriasis, and oncology. Validation of EP 3043825 B1 across selected EPC contracting states extends the company's IP perimeter into European markets where cell and gene therapy regulatory pathways are governed by the EMA's Committee for Advanced Therapies.

The next measurable checkpoint for this program will be how the validated patent geography aligns with the company's clinical site selection and any future manufacturing partnership discussions for its orthopedics and disc degeneration indications.

Source: FibroBiologics, Inc. via PR Newswire, 5 August 2026.